Startups
OncoSec is a biotechnology company pioneering new technologies to stimulate the body’s immune system to target and attack cancer. Through its proprietary DNA gene transfer technology, OncoSec seeks to deliver safer and more effective cancer treatments that can provide long-term benefits for patients who have limited or no available treatment options.
OncoSec’s technology combines TAVO™ (tavokinogene telseplasmid), an intratumoral (IT) DNA plasmid-based interleukin-12 (IL-12) designed to achieve targeted and sustained delivery of IT IL-12. TAVO has demonstrated a local and systemic anti-tumor response in several clinical trials, including preliminary data in a registration directed Phase 2b trial KEYNOTE-695 for anti-PD-1 checkpoint refractory metastatic melanoma and the KEYNOTE-890 Phase 2 trial in metastatic triple-negative breast cancer (mTNBC). To date, preliminary study results have laid the groundwork for the expansion into new DNA-encoded therapeutic candidates and tumor indications. OncoSec plans to develop TAVO, along with other immunologic genes to treat other cancer indications. OncoSec has received both Orphan Drug and Fast-Track Designation by the U.S. Food & Drug Administration for TAVO in metastatic melanoma.
NASDAQ: $ONCS
OncoSec’s technology combines TAVO™ (tavokinogene telseplasmid), an intratumoral (IT) DNA plasmid-based interleukin-12 (IL-12) designed to achieve targeted and sustained delivery of IT IL-12. TAVO has demonstrated a local and systemic anti-tumor response in several clinical trials, including preliminary data in a registration directed Phase 2b trial KEYNOTE-695 for anti-PD-1 checkpoint refractory metastatic melanoma and the KEYNOTE-890 Phase 2 trial in metastatic triple-negative breast cancer (mTNBC). To date, preliminary study results have laid the groundwork for the expansion into new DNA-encoded therapeutic candidates and tumor indications. OncoSec plans to develop TAVO, along with other immunologic genes to treat other cancer indications. OncoSec has received both Orphan Drug and Fast-Track Designation by the U.S. Food & Drug Administration for TAVO in metastatic melanoma.
NASDAQ: $ONCS
Overview
Location
United States, California, San Diego
Employees
51-200
Phone
+1 855-662-6732
Total raised
$73.8M
Founded date
2011
Funding Rounds 4
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
| Sep 4, 2018 | Funding round | $15M | |
| Nov 14, 2017 | Funding round | $9.3M | |
| Nov 4, 2015 | Funding round | $7.5M |
Mentions in press and media 24
Show more
Reviews 0
FAQ about OncoSec
When was OncoSec founded?
OncoSec was founded in 2011.
How much funding has OncoSec raised?
OncoSec has raised $73.8M in total across 4 funding rounds.
What funding rounds has OncoSec raised?
Parsers VC lists 4 funding rounds of OncoSec, among them a funding round of $15M on Sep 4, 2018, a funding round of $9.3M on Nov 14, 2017 and a funding round of $7.5M on Nov 4, 2015.
What has the press written about OncoSec?
Parsers VC has collected 24 articles mentioning OncoSec, among them “OncoSec Enters into a Collaboration Agreement with Merck for a Pivotal Global Phase 3 Study, KEYNOTE-C87, of TAVO™ Combined with KEYTRUDA® for Late-Stage Met...” (Jul 6, 2021) and “OncoSec Receives CE Mark Certification for its Commercial Electroporation Device "GenPulse™" for the Treatment of Solid Tumors” (Apr 14, 2021).
Is OncoSec still active?
Yes, OncoSec is active; its latest activity on Parsers VC dates from Apr 10, 2023.